Agency issued two warning letters to operators of websites that illegally market potentially dangerous, unapproved and misbranded opioid medications.
FDA takes new enforcement actions as part of the agency’s ongoing effort to combat the illegal online sales of opioids
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA In Brief: FDA Hosts Third Summit Focused on Reducing the Availability of Opioids Online
- Coronavirus (COVID-19) Update: September 17, 2021
- Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture and Distribution of Drugs Due to Insanitary Conditions
- Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits – Letter to Clinical Laboratory Staff and Health Care Providers